Navigation Links
Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress
Date:1/24/2008

nationally. The conference ID is 37076673. Please dial in approximately ten minutes prior to the start of the call. A telephone replay will be available beginning approximately one hour after the call through January 31, 2008 and may be accessed by dialing 888-286-8010 from the United States and Canada or 617-801-6888 internationally. The replay passcode is 33900859.

To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of Cardica's website at http://www.cardica.com. Please connect to the website at least 15 minutes prior to the call to allow for any necessary software downloads.

About Cardica, Inc.

Cardica is a leading provider of automated anastomosis systems for coronary artery bypass graft (CABG) surgery. By replacing hand-sewn sutures with easy-to-use automated systems, Cardica's products provide cardiovascular surgeons with rapid, reliable and consistently reproducible anastomoses, or connections of blood vessels, often considered the most critical aspect of the CABG procedure. Cardica's C-Port(R) Distal Anastomosis Systems are marketed in Europe and the United States. The PAS-Port(R) Proximal Anastomosis System is marketed in Europe and Japan and is being evaluated in a pivotal trial in the United States and Europe. Cardica also is developing additional devices with Cook Incorporated to facilitate vascular closure and other surgical procedures.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements under the heading "Financial Guidance for Fiscal 2008." The words "anticipate," "expect," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Cardica's current expectations. Forward-looking statements involve risks and uncertainties. Cardica's actual results and the timing o
'/>"/>

SOURCE Cardica, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cardica and Intuitive Surgical to Host Educational Symposium on Advanced Techniques and Technologies in Robotic Coronary Revascularization and Mitral Valve Repair
2. Cardica and Cook Sign Agreement to Expand Cook Vascular Closure Device Product Family
3. Cardica Receives European CE Mark for C-Port Flex A System for Use in Coronary Artery Bypass Surgery
4. Cardicas C-Port(R) Flex A Anastomosis System Allows Surgeons to Perform Revolutionary Closed-Chest Heart Bypass Surgeries
5. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
6. Gerson Lehrman Group Announces Partnership With BIO to Provide Scientific Expertise for the BIO CEO & Investor Conference
7. Accuray Announces New Treatment Planning Service Offering
8. QED International Associates Announces Changes to the HealthShares(TM) Composite, HealthShares(TM) Cancer and HealthShares(TM) Neuroscience Indexes
9. Sharps Compliance Corp. Announces Purchase of Medical Waste Disposal Facility and Addition of Autoclave Technology
10. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
11. Vapotherm(R) Announces Validation of U.S. Patent

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ries have an opportunity to take the lead in two s...niversity of Valencia (UV), working together with ...e fabric of the Spanish biotechnology industry. Th...ors have more clout than those in English-speaking...nd plants has been overlooked by the leading count...
(Date:11/20/2009)... Cell Therapeutics, Inc. ...the Ninth Circuit Court of Appeals reversed a U.S.... allowed to pursue all of its claims against The L...ourt for trial. CTI filed a complaint against The...t consultant for CTI,s product TRISENOX, in 2007 s...
(Date:11/19/2009)...ewswire-FirstCall/ -- Omeros Corporation (Nasdaq: ...s for the third quarter ended September 30, 2009. ...ros reported a net loss of $3.9 million, or $1.34 ...on, or $2.54 per share, for the same period in 200...he Company reported a net loss of $15.5 million, o...
(Date:11/19/2009)...WALTHAM, Mass., Nov. 19 Arlington ...d that the leading driver of antibiotic selection ...m activity against gram-positive and gram-negative...an cause nosocomial pneumonia, surveyed European p...ts that provide appropriate coverage against commo...
Breaking Biology Technology:Spanish biotechnology should focus on food and plant sectors to be more competitive 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3
... ) today,announced that its Board of Directors has...enior Vice President, Corporate Affairs effective,..., who has announced her,plans to retire., Prior t...dent,Corporate Affairs at ARAMARK since 2003. Duri...cutive roles for several leading companies. He for...
...gies,Inc. (Amex: PTN ) will announce its second q... period ended December 31, 2007 on February 11,200... The Company will also conduct a teleconference an... management team on February 11, 2008 at which,the...r detail and provide,an update on corporate develo...
...ation,(Nasdaq: DRRX ) announced today financial r...r 31, 2007. Total revenues were $6.6 million for t...to $5.4 million for the same,period in 2006. Net l...as,$7.2 million, compared to a net loss of $9.8 mi...//www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO )...
Other Biology Technology:Wyeth Announces Election of Timothy P. Cost as Senior Vice President, Corporate Affairs 2Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th 2DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 2DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 3DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 4DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 5DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 6DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 7DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 8DURECT Corporation Announces Fourth Quarter and Year End 2007 Financial Results 9
(Date:11/19/2009)...ing the genetic instructions inside corn, one of t... of the most complex sequences of DNA ever analyze... David Schwartz, who was one of more than 100 auth...The maize genome is a true maze full of confusing... sequencers for years," says Schwartz. , Publica...
(Date:11/19/2009)...in maize, also known as corn, researchers across t...hould pave the way to significant improvements in ...al feed and fiber around the world. , The new ma... map, charts genetic diversity and recombination a...research team, led by U.S. Department of Agricultu...
(Date:11/19/2009)... T. Ming Chu Professor of Biochemistry and Molecul...ng how regulatory proteins control the production ...rking with collaborators including Drs. Mitchell W...ladelphia, they focused specifically on the comple...es). These cells contain large amounts of hemoglob...
Breaking Biology News(10 mins):Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3New research into the mechanisms of gene regulation 2New research into the mechanisms of gene regulation 3New research into the mechanisms of gene regulation 4New research into the mechanisms of gene regulation 5Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 4661 1Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 4661 2Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement With Genentech 4661 3Mice run faster on high grade oil 9038 1Mice run faster on high grade oil 9038 2Super sleepers could help super sizers 21 9034 1Super sleepers could help super sizers 21 9034 2
...ons to Identify Individuals for Access to ...s, WALL, N.J., Sept. 22 BIO-key International,In...based biometric,identification and wireless public...ork, is showcasing its fingerprint biometric solut...ing held at the Moscone Center in San,Francisco fr...
... 22, 2008) Researchers at the University of Calga... infections in people with cystic fibrosis (CF). T... National Academy of Science USA, this week. , ...e with CF. Pseudomonas aeruginosa is a common bact...ciated with severe lung infections. Pseudomonas re...
...entists and news organizations typically focus on ...s, but research at the University of Michigan sugg...n large numbers of people are the key to understan...ctious disease: cholera. , Using a model develope...d their collaborators came up with results that ch...
Other Biology News:BIO-key(R) International To Exhibit at Oracle OpenWorld 2BIO-key(R) International To Exhibit at Oracle OpenWorld 3BIO-key(R) International To Exhibit at Oracle OpenWorld 4New approach to treating cystic fibrosis lung infection shows promise 2Hidden infections crucial to understanding, controlling disease outbreaks 2Hidden infections crucial to understanding, controlling disease outbreaks 3
Human HGF, Unconjugated from R&D Systems
Anti-alpha1-Antitrypsin Monoclonal Antibody, Unconjugated from CHEMICON
Senescence Colorimetric Assay Kit from BioVision
Mouse LIGHT / TNFSF14, Unconjugated from R&D Systems
Biology Products: